Key result
Subsequent exposure to ticlopidine in patients with prior allergic or hematologic reactions to clopidogrel resulted in a similar reaction in 27%, with no life-threatening events.
Why the study?
Does switching to an alternative thienopyridine cause cross-reactivity in patients with an allergic or hematologic adverse reaction to the first thienopyridine?
Observational (n=76)
Yes
Does switching to an alternative thienopyridine cause cross-reactivity in patients with an allergic or hematologic adverse reaction to the first thienopyridine?
Patients with an allergic or hematologic reaction to one thienopyridine have a 27% risk of a similar, but non-life-threatening, reaction to the alternative thienopyridine.
Answers are grounded in this paper and cite their sources.
May support cautious ticlopidine trial after clopidogrel reactions; leaves open randomized confirmation of cross-reactivity risk.
BACKGROUND: Clopidogrel and ticlopidine are structurally very similar. In patients with an allergic or hematologic adverse reaction to either one of these drugs, the likelihood that an allergic or hematologic adverse effect will develop to the other is unknown. It is also unknown whether a reaction to the second thienopyridine is likely to be life threatening. METHODS AND RESULTS: Medical records from 2 academic institutions were reviewed to identify patients who had an allergic or hematologic adverse reaction to either of the 2 currently commercially available thienopyridines and who were subsequently prescribed the other thienopyridine. Patient demographics, details of the adverse reactions, and subsequent clinical course were reviewed. A total of 76 patients were identified with an allergic or hematologic adverse reaction to clopidogrel or ticlopidine who had also received the other thienopyridine. Fourteen (27%; 95% CI, 16 to 41) patients who had an allergic or hematologic adverse reactions to clopidogrel had a similar reaction to ticlopidine; none developed a life-threatening reaction. The most common reaction was a rash (93%). CONCLUSIONS: In patients with an allergic or hematologic adverse reaction to one thienopyridine, there seems to be an increased frequency of such reactions to the other thienopyridine. However, no patient had a life-threatening reaction after exposure to the alternative thienopyridine.
No takes yet. Share an insight, caveat, or question.
Lokhandwala et al. (2009) conducted an observational in Allergic or hematologic adverse reaction to clopidogrel or ticlopidine (n=76). Alternative thienopyridine (ticlopidine or clopidogrel) was evaluated on Similar allergic or hematologic adverse reaction to the alternative thienopyridine (95% CI 16-41). Subsequent exposure to ticlopidine in patients with prior allergic or hematologic reactions to clopidogrel resulted in a similar reaction in 27%, with no life-threatening events.
Synapse has enriched 10 related papers. Consider them for comparative context: